Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution

Cell

Volumn 165, Issue 1, 2016, Pages 234-246

  Zhao, Boyang ^a   Sedlak, Joseph C ^e   Srinivas, Raja ^b,c   Creixell, Pau ^a   Pritchard, Justin R ^a   Tidor, Bruce ^b,c,d   Lauffenburger, Douglas A ^a,b   Hemann, Michael T ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b USA   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d Department of Electrical Engineering and Computer Science   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; BCR ABL PROTEIN; BCR ABL1 PROTEIN; BOSUTINIB; CABOZANTINIB; CRIZOTINIB; DASATINIB; FORETINIB; IMATINIB; NILOTINIB; PONATINIB; STAT5 PROTEIN; UNCLASSIFIED DRUG; VANDETANIB; BREAKPOINT CLUSTER REGION PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER SURVIVAL; CLONAL EVOLUTION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CROSS RESISTANCE; DOWN REGULATION; DRUG SENSITIVITY; ENZYME SPECIFICITY; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; GENE FREQUENCY; HYDROGEN BOND; IC90; LIMIT OF DETECTION; MOLECULAR DOCKING; MOUSE; MUTATION RATE; NONHUMAN; OVERALL SURVIVAL; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; RNA SEQUENCE; STEREOSPECIFICITY; TEMPORAL COLLATERAL SENSITIVITY; TUMOR RESISTANCE; TUMOR VOLUME; ANIMAL; BIOLOGICAL MODEL; DRUG RESISTANCE; DRUG SCREENING; GENETICS; PATHOLOGY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

ANIMALS; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; MICE; MODELS, BIOLOGICAL; PHILADELPHIA CHROMOSOME; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTO-ONCOGENE PROTEINS C-BCR;

EID: 84975717783     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2016.01.045     Document Type: Article

References (39)

1. D.I. Andersson, and D. Hughes Antibiotic resistance and its cost: Is it possible to reverse resistance? Nat. Rev. Microbiol. 8 2010 260 271
2. E.J. Andreu, E. Lledó, E. Poch, C. Ivorra, M.P. Albero, J.A. Martínez-Climent, C. Montiel-Duarte, J. Rifón, J. Pérez-Calvo, C. Arbona, and et al. BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells Cancer Res. 65 2005 3264 3272
3. H.E. Bhang, D.A. Ruddy, V. Krishnamurthy Radhakrishna, J.X. Caushi, R. Zhao, M.M. Hims, A.P. Singh, I. Kao, D. Rakiec, P. Shaw, and et al. Studying clonal dynamics in response to cancer therapy using high-complexity barcoding Nat. Med. 21 2015 440 448
4. N. Boulos, H.L. Mulder, C.R. Calabrese, J.B. Morrison, J.E. Rehg, M.V. Relling, C.J. Sherr, and R.T. Williams Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia Blood 117 2011 3585 3595
5. G. Chen, W.A. Mulla, A. Kucharavy, H.-J. Tsai, B. Rubinstein, J. Conkright, S. McCroskey, W.D. Bradford, L. Weems, J.S. Haug, and et al. Targeting the adaptability of heterogeneous aneuploids Cell 160 2015 771 784
6. D. Cortez, G. Reuther, and A.M. Pendergast The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells Oncogene 15 1997 2333 2342
7. P. Creixell, A. Palmeri, C.J. Miller, H.J. Lou, C.C. Santini, M. Nielsen, B.E. Turk, and R. Linding Unmasking determinants of specificity in the human kinome Cell 163 2015 187 201
8. L. Ding, T.J. Ley, D.E. Larson, C.A. Miller, D.C. Koboldt, J.S. Welch, J.K. Ritchey, M.A. Young, T. Lamprecht, M.D. McLellan, and et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing Nature 481 2012 506 510
9. M. Dufies, A. Jacquel, G. Robert, T. Cluzeau, A. Puissant, N. Fenouille, L. Legros, S. Raynaud, J.P. Cassuto, F. Luciano, and P. Auberger Mechanism of action of the multikinase inhibitor Foretinib Cell Cycle 10 2011 4138 4148
10. R. Fisher, L. Pusztai, and C. Swanton Cancer heterogeneity: Implications for targeted therapeutics Br. J. Cancer 108 2013 479 485
11. R.A. Gatenby, A.S. Silva, R.J. Gillies, and B.R. Frieden Adaptive therapy Cancer Res. 69 2009 4894 4903
12. M. Gerlinger, A.J. Rowan, S. Horswell, J. Larkin, D. Endesfelder, E. Gronroos, P. Martinez, N. Matthews, A. Stewart, P. Tarpey, and et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing N. Engl. J. Med. 366 2012 883 892
13. I.J. Griswold, M. MacPartlin, T. Bumm, V.L. Goss, T. O'Hare, K.A. Lee, A.S. Corbin, E.P. Stoffregen, C. Smith, K. Johnson, and et al. Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib Mol. Cell. Biol. 26 2006 6082 6093
14. J.A. Hill, T.R. O'Meara, and L.E. Cowen Fitness trade-offs associated with the evolution of resistance to antifungal drug combinations Cell Rep. 10 2015 809 819
15. L. Imamovic, and M.O.A. Sommer Use of collateral sensitivity networks to design drug cycling protocols that avoid resistance development Sci. Transl. Med. 5 2013 204ra132
16. E. Jabbour, V. Morris, H. Kantarjian, C.C. Yin, E. Burton, and J. Cortes Characteristics and outcomes of patients with V299L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors Blood 120 2012 3382 3383
17. P.B. Jensen, B. Holm, M. Sorensen, I.J. Christensen, and M. Sehested In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: Preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin Br. J. Cancer 75 1997 869 877
18. J.S. Khorashad, T.W. Kelley, P. Szankasi, C.C. Mason, S. Soverini, L.T. Adrian, C.A. Eide, M.S. Zabriskie, T. Lange, J.C. Estrada, and et al. BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: Frequency and clonal relationships Blood 121 2013 489 498
19. S. Kim, T.D. Lieberman, and R. Kishony Alternating antibiotic treatments constrain evolutionary paths to multidrug resistance Proc. Natl. Acad. Sci. USA 111 2014 14494 14499
20. V. Lázár, I. Nagy, R. Spohn, B. Csörgo, Á. Györkei, Á. Nyerges, B. Horváth, A. Vörös, R. Busa-Fekete, M. Hrtyan, and et al. Genome-wide analysis captures the determinants of the antibiotic cross-resistance interaction network Nat. Commun. 5 2014 4352
21. N.M. Levinson, and S.G. Boxer Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domain PLoS ONE 7 2012 e29828
22. N.M. Levinson, and S.G. Boxer A conserved water-mediated hydrogen bond network defines bosutinib's kinase selectivity Nat. Chem. Biol. 10 2014 127 132
23. S. Misale, R. Yaeger, S. Hobor, E. Scala, M. Janakiraman, D. Liska, E. Valtorta, R. Schiavo, M. Buscarino, G. Siravegna, and et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer Nature 486 2012 532 536
24. M. Modugno, E. Casale, C. Soncini, P. Rosettani, R. Colombo, R. Lupi, L. Rusconi, D. Fancelli, P. Carpinelli, A.D. Cameron, and et al. Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358 Cancer Res. 67 2007 7987 7990
25. T. O'Hare, M.S. Zabriskie, A.M. Eiring, and M.W. Deininger Pushing the limits of targeted therapy in chronic myeloid leukaemia Nat. Rev. Cancer 12 2012 513 526
26. O.G. Ottmann, and H. Pfeifer Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) Hematology Am. Soc. Hematol. Educ. Program 2009 2009 371 381
27. T. Pemovska, E. Johnson, M. Kontro, G.A. Repasky, J. Chen, P. Wells, C.N. Cronin, M. McTigue, O. Kallioniemi, K. Porkka, and et al. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation Nature 519 2015 102 105
28. F. Ravandi, S. O'Brien, D. Thomas, S. Faderl, D. Jones, R. Garris, S. Dara, J. Jorgensen, P. Kebriaei, R. Champlin, and et al. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia Blood 116 2010 2070 2077
29. L. Rickardson, M. Fryknäs, C. Haglund, H. Lövborg, P. Nygren, M.G. Gustafsson, A. Isaksson, and R. Larsson Screening of an annotated compound library for drug activity in a resistant myeloma cell line Cancer Chemother. Pharmacol. 58 2006 749 758
30. K. Robasky, N.E. Lewis, and G.M. Church The role of replicates for error mitigation in next-generation sequencing Nat. Rev. Genet. 15 2014 56 62
31. N.P. Shah, J.M. Nicoll, B. Nagar, M.E. Gorre, R.L. Paquette, J. Kuriyan, and C.L. Sawyers Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia Cancer Cell 2 2002 117 125
32. B.J. Skaggs, M.E. Gorre, A. Ryvkin, M.R. Burgess, Y. Xie, Y. Han, E. Komisopoulou, L.M. Brown, J.A. Loo, E.M. Landaw, and et al. Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants Proc. Natl. Acad. Sci. USA 103 2006 19466 19471
33. S. Soverini, S. Colarossi, A. Gnani, G. Rosti, F. Castagnetti, A. Poerio, I. Iacobucci, M. Amabile, E. Abruzzese, E. Orlandi, et al. GIMEMA Working Party on Chronic Myeloid Leukemia Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia Clin. Cancer Res. 12 2006 7374 7379
34. G.W. Swan Role of optimal control theory in cancer chemotherapy Math. Biosci. 101 1990 237 284
35. P. Valent, E. Hadzijusufovic, G.H. Schernthaner, D. Wolf, D. Rea, and P. le Coutre Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors Blood 125 2015 901 906
36. R.T. Williams, M.F. Roussel, and C.J. Sherr Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia Proc. Natl. Acad. Sci. USA 103 2006 6688 6693
37. R.T. Williams, W. den Besten, and C.J. Sherr Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemia Genes Dev. 21 2007 2283 2287
38. M.S. Zabriskie, C.A. Eide, S.K. Tantravahi, N.A. Vellore, J. Estrada, F.E. Nicolini, H.J. Khoury, R.A. Larson, M. Konopleva, J.E. Cortes, and et al. BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia Cancer Cell 26 2014 428 442
39. B. Zhao, J.R. Pritchard, D.A. Lauffenburger, and M.T. Hemann Addressing genetic tumor heterogeneity through computationally predictive combination therapy Cancer Discov. 4 2014 166 174